No king without a crown-impact of the nanomaterial-protein corona on nanobiomedicine

Nanomedicine

Volumn 10, Issue 3, 2015, Pages 503-519

  Docter, Dominic ^a   Strieth, Sebastian ^a   Westmeier, Dana ^a   Hayden, Oliver ^b   Gao, Mingyuan ^c   Knauer, Shirley K ^d   Stauber, Roland H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b SIEMENS AG   (Germany)

^c INSTITUTE OF CHEMISTRY   (China)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

bioinformatics; blood system; colloidal chemistry; label free quantification; mass spectrometry; nanomaterials; nanomedicine; nanotoxicology; proteomics

Indexed keywords

NANOMATERIAL; PROTEIN; PROTEIN CORONA; UNCLASSIFIED DRUG; PLASMA PROTEIN; PROTEIN BINDING;

FUNCTIONS OF THE HEMIC, LYMPHATIC AND RETICULOENDOTHELIAL SYSTEMS; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NANOMEDICINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; ANIMAL; CHEMISTRY; HUMAN; METABOLISM; NANOTECHNOLOGY; PROCEDURES;

ANIMALS; BLOOD PROTEINS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; PROTEIN BINDING;

EID: 84923605584     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.184     Document Type: Review

References (116)

1. Rauscher H, Sokull-Kluttgen B, Stamm H. The European Commission's recommendation on the definition of nanomaterial makes an impact. Nanotoxicology 7, 1195-1197 (2013
2. Reese M. Nanotechnology: using co-regulation to bring regulation of modern technologies into the 21st century. Health Matrix Clevel. 23(2), 537-572 (2013
3. Webster TJ. Interview: nanomedicine: past, present and future. Nanomedicine (Lond.) 8(4), 525-529 (2013
4. Pautler M, Brenner S. Nanomedicine: promises and challenges for the future of public health. Int. J. Nanomedicine 5, 803-809 (2012
5. Ranganathan R, Madanmohan S, Kesavan A., et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications. Int. J. Nanomedicine 7, 1043-1060 (2012
6. Ventola CL. The nanomedicine revolution: part 3: regulatory and safety challenges. P T. 37(11), 631-639 (2012
7. Mcneil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(3), 264-271 (2009
8. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine - challenge and perspectives. Angew Chem. Int. Ed. Engl. 48(5), 872-897 (2009
9. Wahajuddin , Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int. J. Nanomedicine 7, 3445-3471 (2012
10. Kim CS, Tonga GY, Solfiell D, Rotello VM. Inorganic nanosystems for therapeutic delivery: status and prospects. Adv. Drug Deliv. Rev. 65(1), 93-99 (2012
11. Mckendry RA. Nanomechanics of superbugs and superdrugs: new frontiers in nanomedicine. Biochem. Soc. Trans. 40(4), 603-608 (2012
12. Meister S, Zlatev I, Stab J., et al. Nanoparticulate flurbiprofen reduces amyloid-beta42 generation in an in vitro blood-brain barrier model. Alzheimers Res. Ther. 5(6), 51 (2013
13. Mi Y, Guo Y, Feng SS. Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond.) 7(12), 1791-1794 (2012
14. Mout R, Moyano DF, Rana S, Rotello VM. Surface functionalization of nanoparticles for nanomedicine. Chem. Soc. Rev. 41(7), 2539-2544 (2012
15. Saraceno R, Chiricozzi A, Gabellini M, Chimenti S. Emerging applications of nanomedicine in dermatology. Skin Res. Technol. 19(1), e13-e19 (2013
16. Strieth S, Nussbaum CF, Eichhorn ME., et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int. J. Cancer 122(2), 452-460 (2008
17. Wang K, Wu X, Wang J, Huang J. Cancer stem cell theory: therapeutic implications for nanomedicine. Int. J. Nanomedicine 8, 899-908 (2013
18. Zarbin MA, Montemagno C, Leary JF, Ritch R. Nanomedicine for the treatment of retinal and optic nerve diseases. Curr. Opin. Pharmacol. 13(1), 134-148 (2013
19. Zhu M, Nie G, Meng H, Xia T, Nel A, Zhao Y. Physicochemical properties determine nanomaterial cellular uptake, transport, and fate. Acc. Chem. Res. (2012
20. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr. Opin. Biotechnol. 24(6), 1159-1166 (2013
21. Seeney C, Ojwang JO, Weiss RD, Klostergaard J. Magnetically vectored platforms for the targeted delivery of therapeutics to tumors: history and current status. Nanomedicine (Lond.) 7(2), 289-299 (2012
22. Prabhu P, Patravale V. The upcoming field of theranostic nanomedicine: an overview. J. Biomed. Nanotechnol. 8(6), 859-882 (2012
23. Murday JS, Siegel RW, Stein J, Wright JF. Translational nanomedicine: status assessment and opportunities. Nanomedicine (Lond.) 5(3), 251-273 (2009
24. Ferrari M. Nanogeometry: beyond drug delivery. Nat. Nanotechnol. 3(3), 131-132 (2008
25. Qian X, Peng XH, Ansari DO., et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotechnol. 26(1), 83-90 (2008
26. Ventola CL. The nanomedicine revolution: part 2: current and future clinical applications. P T. 37(10), 582-591 (2012
27. Hou Y, Qiao R, Fang F., et al. NaGdF4 nanoparticle-based molecular probes for magnetic resonance imaging of intraperitoneal tumor xenografts in vivo. ACS Nano 7(1), 330-338 (2013
28. Hu FQ, Wei L, Zhou Z, Ran YL, Li Z, Gao MY. Preparation of biocompatible magnetite nanocrystals for in vivo magnetic resonance detection of cancer. Adv. Mater. 18(19), 2553-2556 (2006
29. Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed. Res. Int. 2013, 942916 (2013
30. Asharani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and genotoxicity of silver nanoparticles in human cells. ACS Nano 3(2), 279-290 (2009
31. Lunov O, Syrovets T, Rocker C., et al. Lysosomal degradation of the carboxydextran shell of coated superparamagnetic iron oxide nanoparticles and the fate of professional phagocytes. Biomaterials 31(34), 9015-9022 (2010
32. Johnston HJ, Hutchison G, Christensen FM, Peters S, Hankin S, Stone V. A review of the in vivo and in vitro toxicity of silver and gold particulates: particle attributes and biological mechanisms responsible for the observed toxicity. Crit. Rev. Toxicol. 40(4), 328-346 (2010
33. Ju-Nam Y, Lead JR. Manufactured nanoparticles: an overview of their chemistry, interactions and potential environmental implications. Sci. Total Environ. 400(1-3), 396-414 (2008
34. Li N, Xia T, Nel AE. The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles. Free Radic. Biol. Med. 44(9), 1689-1699 (2008
35. Stone V, Johnston H, Clift MJ. Air pollution, ultrafine and nanoparticle toxicology: cellular and molecular interactions. IEEE Trans. Nanobioscience 6(4), 331-340 (2007
36. Nystrom AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J. Control. Release 161(2), 403-408 (2012
37. Bawa R. Regulating nanomedicine - can the FDA handle it?. Curr. Drug Deliv. 8(3), 227-234 (2011
38. Baun A, Hansen SF. Environmental challenges for nanomedicine. Nanomedicine (Lond.) 3(5), 605-608 (2008
39. Rahman M, Ahmad MZ, Kazmi I., et al. Emergence of nanomedicine as cancer targeted magic bullets. recent development and need to address the toxicity apprehension. Curr. Drug Discov. Technol. 9(4), 319-329 (2012
40. Oberdorster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 267(1), 89-105 (2010
41. Oberdorster G. Nanotoxicology: in vitro-in vivo dosimetry. Environ. Health Perspect. 120(1), A13; author reply A13 (2012
42. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J. Control. Release 142(3), 416-421 (2010
43. Monopoli MP, Walczyk D, Campbell A., et al. Physical-chemical aspects of protein corona. relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133(8), 2525-2534 (2011
44. Jeong SK, Kwon MS, Lee EY., et al. BiomarkerDigger: a versatile disease proteome database and analysis platform for the identification of plasma cancer biomarkers. Proteomics 9(14), 3729-3740 (2009
45. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56(2), 177-185 (2011
46. Nel AE, Madler L, Velegol D., et al. Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater. 8(7), 543-557 (2009
47. Tenzer S, Docter D, Kuharev J., et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772-781 (2013
48. Monopoli MP, Bombelli FB, Dawson KA. Nanobiotechnology: nanoparticle coronas take shape. Nat. Nanotechnol. 6(1), 11-12 (2011
49. Klein J. Probing the interactions of proteins and nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2029-2030 (2007
50. Cedervall T, Lynch I, Lindman S., et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2050-2055 (2007
51. Treuel L, Malissek M. Interactions of nanoparticles with proteins: determination of equilibrium constants. Methods Mol. Biol. 991, 225-235 (2013
52. Lacerda SH, Park JJ, Meuse C., et al. Interaction of gold nanoparticles with common human blood proteins. ACS Nano 4(1), 365-379 (2010
53. Gebauer JS, Malissek M, Simon S., et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir 28(25), 9673-9679 (2012
54. Monopoli MP, Aberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotechnol. 7(12), 779-786 (2012
55. Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson KA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265-14270 (2008
56. Walkey CD, Olsen JB, Song F., et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8(3), 2439-2455 (2014
57. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, Dawson KA. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv. Colloid Interface Sci. 134-135, 167-174 (2007
58. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. What the cell 'sees' in bionanoscience. J. Am. Chem. Soc. 132(16), 5761-5768 (2010
59. Treuel L, Brandholt S, Maffre P, Wiegele S, Shang L, Nienhaus GU. Impact of protein modification on the protein corona on nanoparticles and nanoparticle-cell interactions. ACS Nano 8(1), 503-513 (2014
60. Treuel L, Eslahian KA, Docter D., et al. Physicochemical characterization of nanoparticles and their behavior in the biological environment. Phys. Chem. Chem. Phys. 16(29), 15053-15067 (2014
61. Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int. J. Pharm. 392(1-2), 261-267 (2010
62. Wolfram J, Yang Y, Shen J., et al. The nano-plasma interface. Implications of the protein corona. Colloids Surf. B Biointerfaces 124, 17-24 (2014
63. Leszczynski J. Bionanoscience: Nano meets bio at the interface. Nat. Nanotechnol. 5(9), 633-634 (2010
64. Adiseshaiah PP, Hall JB, Mcneil SE. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2(1), 99-112 (2010
65. Dobrovolskaia MA, Neun BW, Man S., et al. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. Nanomedicine (Lond.) 10(7), 1453-1463 (2014
66. Tenzer S, Docter D, Rosfa S., et al. Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5(9), 7155-7167 (2011
67. Thomas CR, George S, Horst AM., et al. Nanomaterials in the environment. from materials to high-Throughput screening to organisms. ACS Nano 5(1), 13-20 (2011
68. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for characterization of nanomaterials in biological systems. Nat. Nanotechnol. 5(9), 671-675 (2010
69. Zhang H, Burnum KE, Luna ML., et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics 11(23), 4569-4577 (2011
70. Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134(4), 2139-2147 (2012
71. Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41(7), 2780-2799 (2012
72. Caracciolo G, Pozzi D, Capriotti AL., et al. Evolution of the protein corona of lipid gene vectors as a function of plasma concentration. Langmuir 27(24), 15048-15053 (2011
73. Lundqvist M, Stigler J, Cedervall T., et al. The evolution of the protein corona around nanoparticles. a test study. ACS Nano 5(9), 7503-7509 (2011
74. Mahmoudi M, Abdelmonem AM, Behzadi S., et al. Temperature. the 'ignored' factor at the NanoBio interface. ACS Nano 7(8), 6555-6562 (2013
75. Barran-Berdon AL, Pozzi D, Caracciolo G., et al. Time evolution of nanoparticle-protein corona in human plasma. relevance for targeted drug delivery. Langmuir 29(21), 6485-6494 (2013
76. Casals E, Pfaller T, Duschl A, Oostingh GJ, Puntes V. Time evolution of the nanoparticle protein corona. ACS Nano 4(7), 3623-3632 (2010
77. Dell'orco D, Lundqvist M, Oslakovic C, Cedervall T, Linse S. Modeling the time evolution of the nanoparticle-protein corona in a body fluid. PLoS ONE 5(6), e10949 (2010
78. Natte K, Friedrich JF, Wohlrab S., et al. Impact of polymer shell on the formation and time evolution of nanoparticle-protein corona. Colloids Surf. B Biointerfaces 104, 213-220 (2013
79. Rocker C, Potzl M, Zhang F, Parak WJ, Nienhaus GU. A quantitative fluorescence study of protein monolayer formation on colloidal nanoparticles. Nat. Nanotechnol. 4(9), 577-580 (2009
80. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdorster G, Mcgrath JL. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. Biomaterials 30(4), 603-610 (2009
81. Goppert TM, Muller RH. Protein adsorption patterns on poloxamer- And poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 60(3), 361-372 (2005
82. Labarre D, Vauthier C, Chauvierre C, Petri B, Muller R, Chehimi MM. Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 26(24), 5075-5084 (2005
83. Lindman S, Lynch I, Thulin E, Nilsson H, Dawson KA, Linse S. Systematic investigation of the thermodynamics of HSA adsorption to N-iso-propylacrylamide/N-Tert-butylacrylamide copolymer nanoparticles. Effects of particle size and hydrophobicity. Nano. Lett. 7(4), 914-920 (2007
84. Owens DE 3rd, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93-102 (2006
85. Chakraborty S, Joshi P, Shanker V, Ansari ZA, Singh SP, Chakrabarti P. Contrasting effect of gold nanoparticles and nanorods with different surface modifications on the structure and activity of bovine serum albumin. Langmuir 27(12), 7722-7731 (2011
86. Dobrovolskaia MA, Patri AK, Zheng J., et al. Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles. Nanomedicine (Lond.) 5(2), 106-117 (2009
87. Dutta D, Sundaram SK, Teeguarden JG., et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. Toxicol. Sci. 100(1), 303-315 (2007
88. Gessner A, Lieske A, Paulke B, Muller R. Influence of surface charge density on protein adsorption on polymeric nanoparticles: analysis by two-dimensional electrophoresis. Eur. J. Pharm. Biopharm. 54(2), 165-170 (2002
89. Mahmoudi M, Shokrgozar MA, Sardari S., et al. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles. Nanoscale 3(3), 1127-1138 (2011
90. Mahmoudi M, Sant S, Wang B, Laurent S, Sen T. Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv. Drug Deliv. Rev. 63(1-2), 24-46 (2011
91. Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, Mcneil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428-437 (2009
92. Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small 6(1), 12-21 (2010
93. Barkam S, Saraf S, Seal S. Fabricated micro-nano devices for in vivo and in vitro biomedical applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5(6), 544-568 (2013
94. Farrah T, Deutsch EW, Omenn GS., et al. A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas. Mol. Cell. Proteomics 10(9), M110 006353 (2011
95. Dobrovolskaia MA, Mcneil SE. Immunological properties of engineered nanomaterials. Nat. Nanotechnol. 2(8), 469-478 (2007
96. Dobrovolskaia MA, Aggarwal P, Hall JB, Mcneil SE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5(4), 487-495 (2008
97. Helou M, Reisbeck M, Tedde SF., et al. Time-of-flight magnetic flow cytometry in whole blood with integrated sample preparation. Lab Chip 13(6), 1035-1038 (2013
98. Eichhorn ME, Strieth S, Krasnici S., et al. Protamine enhances uptake of cationic liposomes in angiogenic microvessels. Angiogenesis 7(2), 133-141 (2004
99. Xia T, Li N, Nel AE. Potential health impact of nanoparticles. Ann. Rev. Public Health 30, 137-150 (2009
100. Capriotti A, Caracciolo G, Cavaliere C., et al. Analytical methods for characterizing the nanoparticle protein corona. Chromatographia 77(11-12), 755-769 (2014
101. Nahnsen S, Bielow C, Reinert K, Kohlbacher O. Tools for label-free peptide quantification. Mol. Cell. Proteomics 12(3), 549-556 (2013
102. Docter D, Bantz C, Westmeier D., et al. The protein-corona protects against size- And dose-dependent toxicity of amorphous silica nanoparticles. Beilstein J. Nanotechnol. 5, 1380-1392. (2014
103. Salvati A, Pitek AS, Monopoli MP., et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 8(2), 137-143 (2013
104. Vroman L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature 196, 476-477 (1962
105. Milani S, Baldelli Bombelli F, Pitek AS, Dawson KA, Radler J. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: soft and hard corona. ACS Nano 6(3), 2532-2541 (2012
106. Moghimi SM, Farhangrazi ZS. Nanomedicine and the complement paradigm. Nanomedicine 9(4), 458-460 (2013
107. Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: What does the cell see?. Nat. Nanotechnol. 4(9), 546-547 (2009
108. Sacchetti C, Motamedchaboki K, Magrini A., et al. Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano 7(3), 1974-1989 (2013
109. Murthy AK, Stover RJ, Borwankar AU., et al. Equilibrium gold nanoclusters quenched with biodegradable polymers. ACS Nano 7(1), 239-251 (2013
110. Pozzi D, Colapicchioni V, Caracciolo G., et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale 6(5), 2782-2792 (2014
111. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 4(7), 411-414 (2009
112. Von Maltzahn G, Park JH, Lin KY., et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat. Mater. 10(7), 545-552 (2012
113. Muthu MS, Feng SS. Targeted nanomedicine for detection and treatment of circulating tumor cells. Nanomedicine (Lond.) 6(4), 579-581 (2011
114. Vogler EA. Protein adsorption in three dimensions. Biomaterials 33(5), 1201-1237 (2012
115. Dell'orco D, Lundqvist M, Cedervall T, Linse S. Delivery success rate of engineered nanoparticles in the presence of the protein corona: a systems-level screening. Nanomedicine 8(8), 1271-1281 (2012
116. Hu W, Peng C, Lv M., et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 5(5), 3693-3700 (2011